Roivant Sciences (ROIV) Accumulated Expenses (2021 - 2026)

Roivant Sciences (ROIV) has 6 years of Accumulated Expenses data on file, last reported at $205.8 million in Q1 2026.

• Quarterly Accumulated Expenses rose 80.08% year-over-year to $205.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $205.8 million (up 80.08% YoY) and the FY2026 annual result came in at $205.8 million, up 80.08% from the prior year.
• Accumulated Expenses rose to $205.8 million in Q1 2026, from $118.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $205.8 million in Q1 2026 to a low of $26.5 million in Q2 2025.
• A 5-year average of $93.1 million and a median of $108.3 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses soared 262.82% — and 2025, when it slumped 80.81%.
• Tracing ROIV's Accumulated Expenses over 5 years: stood at $41.9 million in 2022, then jumped by 83.46% to $76.9 million in 2023, then surged by 35.66% to $104.3 million in 2024, then increased by 13.1% to $118.0 million in 2025, then jumped by 74.44% to $205.8 million in 2026.
• The last three Accumulated Expenses figures came in at $205.8 million (Q1 2026), $118.0 million (Q4 2025), and $108.3 million (Q3 2025), per Business Quant data.